Ardelyx, Inc. (ARDX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

12/25

Growth 4 Margin 3 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

12
Ardelyx (ARDX) Q2 2026: 31% Revenue Growth Met by Access Hurdles, Profitability Target Reaffirmed for 2027
August 07, 2026
16
Ardelyx (ARDX) Q1 2026: Ibsrella Revenue Jumps 58% as Specialty Channel Drives Prescription Fulfillment
May 01, 2026
14
Ardelyx (ARDX) Q4 2025: Ibsrella Surges 73% as Pipeline and IP Expansion Anchor $1B Ambition
February 24, 2026
18
Ardelyx (ARDX) Q3 2025: Ibsrella Surges 92% as Pipeline and Cash Position Reinvigorate Growth Ambitions
October 31, 2025
Ardelyx (ARDX) Q2 2025: Ibsrella Net Sales Surge 84% as Field Execution Drives Guidance Raise
August 05, 2025
11
Ardelyx (ARDX) Q1 2025: Absrella Revenue Jumps 57% as Field Expansion Drives IBSC Momentum
July 04, 2025
Ardelyx (ARDX) Q3 2024: Exposa Sales Jump 39% as Medicare Bundle Uncertainty Intensifies
October 31, 2024
Ardelyx (ARDX) Q2 2024: Exposa Revenue Surges 145%, Raising Stakes in Medicare Access Fight
August 01, 2024
Ardelyx (ARDX) Q1 2024: Exposa Launch Delivers $15.2M as Nephrology Adoption Accelerates
May 02, 2024
Ardelyx (ARDX) Q4 2023: Ibsrella Sales Up 26% QoQ, Fueling $140M+ 2024 Outlook
February 22, 2024
Ardelyx (ARDX) Q3 2023: Ibsrella Jumps 22% as Exposa Launch Targets 550K-Patient CKD Market
October 31, 2023
Ardelyx (ARDX) Q4 2022: Ibsrella Sales Jump 78% as Launch Momentum Builds for Exposa
March 02, 2023

Browse all companies